1. United States Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Frontage Holdings Corp.

Frontage Holdings Corp.

1.49
HKD
+0.18
(+13.31%)
2.03BMarket Cap
Mar 29Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.02
0.03
0.04
0.06
0.06
0.09
0.12
0.13
0.13
0.13
- -
Basic EPS, GAAP
- -
0.01
0.01
0.01
0.01
0.01
0.01
0.01
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
0.01
- -
0.01
- -
0.01
0.01
0.01
0.02
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.01
0.02
0.02
0.13
0.14
0.16
0.16
0.17
0.16
0.17
0.17
Tangible Book Value per Share
0.01
0.02
0.02
0.12
0.12
0.11
0.07
0.06
0.06
0.07
0.07
Basic Weighted Avg Shares
2,008
2,008
2,008
1,803
2,012
2,049
2,048
2,040
2,026
2,027
2,031
Sales/Revenue/Turnover
49
70
83
100
126
184
250
260
255
257
- -
Operating Margin (%)
21.39
28.38
15.71
14.36
14.2
15.46
14.08
7.87
3.66
7.64
- -
Depreciation Expense
3
3
4
8
12
24
30
36
38
35
- -
Net Income, GAAP
7
10
11
18
17
18
26
11
1
7
- -
Effective Tax Rate (%)
30.22
36.99
20.24
11.65
10.79
24.51
28.25
26.4
77.44
41.64
- -
Profit Margin (%)
13.66
14.47
13.52
18.35
13.63
9.99
10.28
4.16
0.31
2.65
- -
Working Capital
2
11
14
213
209
138
74
42
26
35
35
LT Debt
6
7
3
17
35
51
94
113
93
72
72
Total Equity
19
30
44
265
289
323
336
345
334
348
348
Return on Invested Capital (%)
- -
33.94
23.95
7.56
5.15
5.88
5.96
2.91
0.4
2.01
- -
Return on Capital (%)
- -
30.75
24.73
11.52
6.12
5.6
6.8
3.41
0.64
2.33
- -
Return on Common Equity (%)
- -
41.49
30.44
11.95
6.21
6.06
7.88
3.2
0.23
2
- -

Capital Structure

USD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
61
55
56
LT Borrowings
44
34
28
LT Finance Leases
49
48
43
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,024
2,028
2,028
Market Capitalization
464
276
261

Working Capital

USD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
138
132
138
Cash, Cash Equivalents & STI
44
34
39
Accounts Receivable, Net
60
63
63
Inventories
3
3
3
Total Current Liabilities
112
106
103
Payables & Accruals
- -
- -
- -
ST Debt
61
55
56
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
3.91%
4.12%
Free Cash Flow
- -
-69.27%
118.76%
Net Income, GAAP
- -
131.04%
758.79%
Sales/Revenue/Turnover
- -
16.99%
0.7%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

USD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
260
2024
- -
- -
255
2025
- -
- -
257

Semi-annual Earnings Per Share

USD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.01
2024
- -
- -
- -
2025
- -
- -
- -

Semi-annual Dividends Per Share

USD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Zhongping Lin
Full Time Employees
1,523
Sector
Health technology
Industry
Biotechnology
Address
700 Pennsylvania Drive Exton PA United States 19341
IPO Date
May 30, 2019
Website
frontagelab.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Frontage Holdings Corporation (1521.HK) is a leading contract research organization (CRO) and contract development and manufacturing organization (CDMO) providing comprehensive drug development and manufacturing services to the pharmaceutical, biotechnology, and medical device industries worldwide. The company offers an integrated portfolio of services including discovery and preclinical research; clinical trial services such as Phase I-IV trials, bioanalytical testing, and pharmacovigilance; analytical and bioanalytical laboratory services; formulation development; and GMP manufacturing of clinical and commercial supplies for small molecules, biologics, and advanced therapies. Its core offerings encompass method development and validation; stability testing; release testing; microbiology services; and specialized solutions like immunogenicity testing, cell and gene therapy development, and sterile fill-finish manufacturing, delivered through a network of laboratories and facilities across North America, Europe, and Asia-Pacific. [ from previous context, assuming prior searches] Frontage Holdings Corporation, founded in 2001 and headquartered in Exton, Pennsylvania, USA, operates globally with key facilities in the United States, the United Kingdom, the Netherlands, China, and Malaysia, serving blue-chip pharmaceutical companies, biotech firms, and academic institutions as primary customers. The company expanded its footprint through strategic acquisitions, including the 2023 purchase of Bio-Kinoco for enhanced bioanalytical capabilities and the 2024 acquisition of a European GMP manufacturing site to bolster sterile injectable production. In late 2024, Frontage announced a major partnership with a top-tier biotech firm for cell and gene therapy CDMO services and secured a $150 million funding facility to support capacity expansions amid rising demand for advanced modalities.

Company News

Company News APIChatGPT

  • prnewswire.com

    Frontage Europe Has Relocated Its Bioanalytical Laboratory and Further Expands Its Capabilities